Literature DB >> 8566162

Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors.

R J Knapp1, R Landsman, S Waite, E Malatynska, E Varga, W Haq, V J Hruby, W R Roeske, H Nagase, H I Yamamura.   

Abstract

2-methyl-4a alpha-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12a alpha-octahydro-quinolino[2,3,30g]isoquinoline (TAN-67) is a nonpeptidic delta-opioid receptor agonist. This report describes its receptor binding affinity and agonist potency at human and mouse delta and mu-opioid receptors. The binding affinities of TAN-67 and the cyclic enkephalin analog, (D-Pen2, 4'-Cl-Phe4, D-Pen5]enkephalin (pCl-DPDPE) were measured by radioligand binding inhibition studies at mouse and human variants of the delta and mu-opioid receptor using [3H]Naltrindole and [3H]D-Phe-Cys-Tyr-D-Trp-Orn-Thr -Pen-Thr-NH2, respectively. TAN-67 showed high binding affinity (Ki = 0.647 nM) at the human delta-opioid receptor and high delta-opioid receptor binding selectivity ( > 1000-fold) relative to the human mu-opioid receptor. TAN-67 also showed high potency (EC50 = 1.72 nM) for the inhibition of forskolin-stimulated cAMP accumulation at human delta-opioid receptors expressed by intact Chinese hamster ovary cells but low potency (EC50 = 1520 nM) at human mu-opioid receptors expressed by intact B82 mouse fibroblast cells. The results show that TAN-67 has similar binding affinities, selectivity and potencies as pCl-DPDPE at human delta and mu-opioid receptors. These results combined with the nonpeptidic structure of TAN-67 suggest that this compound has therapeutic potential as a delta-opioid receptor agonist.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8566162     DOI: 10.1016/0922-4106(95)90134-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

2.  Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety.

Authors:  Richard M van Rijn; Daniela I Brissett; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

Review 3.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

4.  Kappa and delta opioid receptor signaling is augmented in the failing heart.

Authors:  Craig Bolte; Gilbert Newman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2009-06-30       Impact factor: 5.000

Review 5.  Pharmacological traits of delta opioid receptors: pitfalls or opportunities?

Authors:  Richard M van Rijn; Julia N Defriel; Jennifer L Whistler
Journal:  Psychopharmacology (Berl)       Date:  2013-05-07       Impact factor: 4.530

Review 6.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

Review 7.  Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.

Authors:  Yazan J Meqbil; Richard M van Rijn
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15

8.  Toward a Universal μ-Agonist Template for Template-Based Alignment Modeling of Opioid Ligands.

Authors:  Zhijun Wu; Victor J Hruby
Journal:  ACS Omega       Date:  2019-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.